Report ID: SQMIG35H2359
Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Pharmaceutical Contract Manufacturing Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Pharmaceutical Contract Manufacturing industry players.
The growing trend in the pharmaceutical contract manufacturing industry is to use contract manufacturing services to cut costs, scale production faster. As pharmaceutical manufacturers become more complex, pharmaceutical companies are increasingly turning to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) that offer specialized services for complex drug compounds. In addition, an increasing number of new therapies are coming on the market, and pharmaceutical manufacturers are looking to contract manufacture for these products to answer both the demand for international markets and the need for improved efficiency in the manufacture of medications.
According to SkyQuest Technology “Pharmaceutical Contract Manufacturing Market By Services (Pharmaceutical Manufacturing Services, Drug Development Services, Biologics Manufacturing Services, Packaging & Labelling Services, Fill-finish Services, Other Services), By End User, By Region- Industry Forecast 2025-2032,” Global Pharmaceutical Contract Manufacturing Market is projected to grow at a CAGR of over 5.9% by 2032, on account of urgent need for automating quantified data. The combination of a strong international demand for pharmaceuticals (driven by aging populations, the growing number of chronic disease patients, and an expanding global market for generic pharmaceuticals) with increased regulatory oversight (e.g., GMP regulations). As a result, many pharmaceutical firms are turning to contract manufacturers to help them lower their costs and improve their ability to manufacture their products more efficiently and quickly.
|
Company |
Est. Year |
Headquarters |
Revenue |
Key Services |
|
Lonza Group |
1897 |
Basel, Switzerland |
USD 8.14 Billion |
Biologics development and manufacturing, small-molecule manufacturing, cell-and-gene therapy production, plasmid and bulk drug substance, formulation and fill-finish |
|
Thermo Fisher Scientific (Patheon) |
1956 |
Waltham, Massachusetts, U.S. |
USD 6.97 Billion |
Small-molecule development, sterile fill-finish, oral solid dosages, biologics manufacturing, API production |
|
Catalent Pharma Solutions |
2007 |
Somerset, New Jersey, U.S. |
USD 4.14 Billion |
Clinical supply services, injectable and oral drug delivery, gene therapy manufacturing, formulation development |
|
Samsung Biologics |
2011 |
Incheon, South Korea |
USD 2.70 Billion |
Large-scale biologics manufacturing, analytical development, cell-line development, process optimization |
|
WuXi Biologics |
2010 |
Wuxi, China |
USD 2.37 Billion |
Biologics R&D, mammalian cell culture, drug substance / drug product manufacturing, single-use bioreactors |
|
Siegfried Holding AG |
1873 |
Zofingen, Switzerland |
USD 1.46 Billion |
Custom small-molecule synthesis, development, sterile manufacturing, route optimisation |
|
Recipharm AB |
1995 |
Stockholm, Sweden |
USD 1.44 Billion |
Oral solids, sterile manufacturing, drug product manufacturing, fill-finish services |
|
FUJIFILM Diosynth Biotechnologies |
1977 |
College Station, Texas, U.S. / Tokyo, Japan |
USD 1.38 Billion |
Biologics manufacturing, gene therapy, microbial production, mammalian cell culture, vaccine production |
|
Boehringer Ingelheim BioXcellence |
1885 |
Ingelheim, Germany |
USD 1.19 Billion |
Biopharmaceutical manufacturing, downstream processing, fermentation, large-scale biologics production |
|
MilliporeSigma / Merck KGaA (CDMO division) |
1954 |
Darmstadt, Germany / Burlington, Massachusetts, U.S. |
USD 790 Million |
Bioprocessing, cell culture, viral vectors, purification, drug substance production |
Lonza Group is one of the largest and most diverse contract development and manufacturing organizations (CDMO) in the world with capabilities covering small molecule (APIs), biologics, cell/gene therapies, as well as advanced biomanufacturing technology. Lonza Group has extensive capabilities for both biologic and non-biologic product development/manufacturing and has the most comprehensive development/manufacturing solutions available today. Additionally, Lonza Group has industry-leading mammalian cell culture capabilities and viral vector manufacturing capabilities, which allow them to offer end-to-end integrated development and manufacturing services.
Thermo Fisher Scientific's Patheon is a leading provider of outsourced pharmaceutical development and manufacturing services, both biologic and small molecule. Thermo Fisher Scientific's extensive integrated analytical, research, and technology platforms enable Patheon to provide complete, integrated development services starting from pre-clinical formulation through to commercial manufacturing.
Catalent is one of the largest contract development and manufacturing organizations (CDMO) in the world, with advanced delivery technologies, including softgel capsules, Zydis tablets, and an extensive injectable formulation platform. Catalent has developed a wide range of clinical supply services, while expanding into the high-growth area of cell and gene therapy manufacturing through a number of acquisitions. Catalent's dedication to innovation, expertise in the various dosage forms of drug delivery, quick-to-market capabilities, makes them a preferred partner for developing complex products.
Samsung Biologics has risen to prominence as a major player within the biotechnology sector due to its explosive growth as one of the world's leading contract development and manufacturing organizations (CDMOs) for biologics to its enormous production capabilities, highly sophisticated manufacturing facilities, and robust customer service capabilities. In addition to traditional monoclonal antibodies and biosimilars, Samsung Biologics provides full-service contract develop and manufacture of next-generation biologics.
WuXi Biologics is a leading contract development and manufacturing organization (CDMO) based in China, having developed a complete range of capabilities for biologics from research through commercialization. WuXi's proprietary "follow-the-molecule" model allows the company to support the complete biologics life cycle seamlessly from start to end.
Based in Switzerland and widely regarded as one of the premier contract development and manufacturing organization (CDMO), Siegfried specializes in synthesizing custom chemicals as well as producing APIs and drug products. With an extensive history of developing small-molecules for a number of pharmaceutical companies and high levels of compliance with the various international regulatory bodies with which it is involved, Siegfried has built a strong reputation within the pharmaceutical industry.
Recipharm is a global contract development and manufacturing organization (CDMO) headquartered in Sweden, providing contract manufacture for an extensive range of dosage forms (including sterile injectables, inhalation products, and oral solids), as well as pharmaceutical development, packaging, and regulatory support.
As a leader in the advanced therapeutic manufacturing and biologic sectors, FUJIFILM Diosynth Biotechnologies provides specialized manufacturing services for the production of advanced therapy products including recombinant proteins, viral vectors, and gene therapy. The company's process development and bioprocessing technology allow FUJIFILM Diosynth to assist customers in every step of the process from early phase through large-scale production.
BioXcellence offers a high level of expertise in both microbial and mammalian cell culture systems as a contract manufacturing organization (CMO) to the biopharmaceutical industry. With this breadth of knowledge and expertise, BioXcellence can assist clients throughout the entire process, from pre-clinical development through large-scale commercial manufacturing, in a highly compliant manner with the highest regulatory standards to the company’s extensive and decades-long experience delivering high-quality biopharmaceuticals. BioXcellence operates numerous global sites and possesses significant bioprocess innovation capabilities, making it a proven CMO for the manufacture of complex biologics and biosimilars in all major international markets.
MilliporeSigma (Merck KGaA), the life sciences division of Merck KGaA, offers an extensive range of specialized contract manufacturing organization (CMO) services specifically designed for the development of biologic drug products.
1. Aenova Group
2. AbbVie Contract Manufacturing
3. Baxter BioPharma Solutions
4. Piramal Pharma Solutions
5. Almac Group
6. Famar Healthcare Services
7. Thermo Fisher Scientific
8. Cambrex Corporation
9. Evonik Health Care
10. Jubilant Pharmova
11. CordenPharma International
12. AMRI
The global pharmaceutical contract manufacturing market is expected to continue to grow as pharmaceutical companies pursue the benefits of outsourcing through increased production efficiency, reduced costs, and the ability to focus on R&D and commercialization. The increasing demand for complex biologics, biosimilars, and personalized medicines will further promote the dependence on CDMOs with advanced technology and regulatory knowledge. As the pharmaceutical industry relies more on outsourcing to meet the demand for global drug products, CMOs and CDMOs will become increasingly important in guaranteeing quality, scalability, and timely delivery of pharmaceuticals. Continuous investments, ongoing technology improvements, and continued growth in global capacity will maintain this market as an important component of the modern global pharmaceutical supply chain.
REQUEST FOR SAMPLE
Global Pharmaceutical Contract Manufacturing Market size was valued at USD 21.31 Billion in 2024 and is poised to grow from USD 22.56 Billion in 2025 to USD 35.69 Billion by 2033, growing at a CAGR of 5.9% in the forecast period (2026–2033).
The pharmaceutical contract manufacturing industry is moderately consolidated, with a mix of global players and region-specific CMOs competing based on service capabilities, technological expertise, regulatory track record, and geographic presence. Leading companies are focusing on expanding their end-to-end service offerings by integrating development, manufacturing, packaging, and even logistics solutions to become full-service CDMOs. Strategic mergers, acquisitions, and capacity expansions continue to shape the competitive landscape. 'Novo Holdings', 'Lonza Group AG', 'CoreRx', 'Catalent Inc.', 'Thermo Fisher Scientific (Patheon)', 'Samsung Biologics', 'Siegfried Holding AG', 'Recipharm AB', 'Fujifilm Diosynth Biotechnologies', 'Boehringer Ingelheim BioXcellence', 'WuXi AppTec', 'Jubilant Pharmova Limited', 'Cambrex Corporation', 'Evonik Industries AG'
Pharmaceutical companies are under increasing pressure to manage soaring R&D and production costs. Outsourcing manufacturing operations to contract manufacturers allows these companies to reduce capital investments in facilities, equipment, and labor. By leveraging the established infrastructure of CMOs, drug makers can streamline operations and focus more on their core activities such as innovation, regulatory filings, and marketing.
Adoption of Smart Manufacturing Technologies: Contract manufacturers are increasingly integrating digital tools such as Artificial Intelligence, automation, and data analytics into their production workflows. These technologies enhance efficiency, enable predictive maintenance, support real-time monitoring, and ensure consistent product quality. AI-driven systems also facilitate faster decision-making and improved batch release processes, giving CMOs a competitive edge.
How is the Pharmaceutical Contract Manufacturing Market Evolving in North America?
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35H2359
sales@skyquestt.com
USA +1 351-333-4748